Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ICAAC 2015: Merck's Bezlotoxumab A 'Big Step' In C Diff

This article was originally published in Scrip

Executive Summary

Merck & Co.'s bezlotoxumab for the treatment of recurrent clostridium difficile (C diff) infections is "a big step" for treatment of the debilitating and potentially deadly gut infection, according to Dale Gerding, a professor at Loyola University Chicago Stritch School of Medicine and a lead investigator for the monoclonal antibody's Phase III clinical trials.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register